Lapatinib

===Pharmacokinetics===

{| class="wikitable" border="1" width="40%" style="text-align:center"

|-

! colspan="6" align="center"| VEGFR Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref><ref>R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)</ref><ref>PMID:16133532</ref><ref>PMID:20821331</ref><ref>PMID:20717111</ref>

|-

! Parameter

! [[Sunitinib]] (Sutent)

! [[Sorafenib]] (Nexavar)

|-

! [[Pharmaceutical_Drugs#Tmax|T_max]] (hr)

! 8

! 8.3

|-

! [[Pharmaceutical_Drugs#Cmax|C_max]] (ng/ml)

! 24.6

! 460

|-

! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)

! Variable

! 29-49

|-

! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)

! 95

! 99

|-

! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T_1/2]] (hr)

! 83

! 29

|-

! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)

! 1921

! 11040

|-

! Dosage (mg)

! 50

! 50

|-

! Metabolism

! Hepatic (CYP3A4)

! Hepatic (CYP3A4)

|}